<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117695">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942369</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52014-210</org_study_id>
    <nct_id>NCT01942369</nct_id>
  </id_info>
  <brief_title>A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months</brief_title>
  <acronym>DIE-NIS</acronym>
  <official_title>A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe changes in the intensity of specific endometriosis
      symptoms from baseline pre-surgery to after surgery and subsequent continuous Diphereline
      (Triptorelin Acetate) treatment for up to 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changes in the intensity of specific endometriosis symptoms from baseline pre-surgery</measure>
    <time_frame>Every 3 months in the first 12 months after surgery and every 6 months in the following 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The specific endometriosis symptoms include pelvic pain, dysmenorrhoea, pain at time of ovulation, dyspareunia to be assessed with a 10-cm visual analogue scale (VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of specific endometriosis symptoms</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recurrence rate of specific endometriosis symptoms in the group of patients with mild or null symptoms score following surgery and Diphereline treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pregnancy in subjects</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal pain-free interval</measure>
    <time_frame>Every 3 months in the first 12 months after surgery and every 6 months in the following 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed using a visual analogue scale (VAS).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Deep Infiltrating Endometriosis (DIE)</condition>
  <arm_group>
    <arm_group_label>Deep Infiltrating Endometriosis (DIE)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Acetate 3.75mg intramuscular injection</intervention_name>
    <description>Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).
Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks.</description>
    <arm_group_label>Deep Infiltrating Endometriosis (DIE)</arm_group_label>
    <other_name>Diphereline 3.75mg intramuscular injection</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients who had been diagnosed with DIE, surgically treated and for whom
        decision has been made to be treated with a GnRHa post-surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with DIE and having received surgery treatment within one month
             before inclusion

          -  Premenopausal women aged &gt;=18 years old.

          -  Patient for whom the treating physician already made the decision to treat by
             Diphereline.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Patients currently on treatment or who have been on therapy with a GnRHa in the last
             6 months.

          -  Premenopausal women who may reach menopause within the 3 years post randomisation.

          -  Hypersensitivity to Triptorelin or one of the excipients of Triptorelin 3.75mg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Uro-Oncology</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Women's Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triptorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
